Onyx seeks expedited FDA review of myeloma drug carfilzomib

09/28/2011 | Xconomy

Onyx Pharmaceuticals has asked the FDA for priority evaluation of carfilzomib, a treatment candidate for multiple myeloma. Clinical data show that the drug reduces tumor size in patients who have received at least two previous therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC